OutcomesOutcome
Psoriasis Area and Severity Index (PASI) score
2 findings from 2 compounds ↓reported in points (0-72 scale), or percent change from baseline as recorded with each finding
What moved it
How to read these marks2 findings · 2 compounds · 2 null · by evidence strength. No dose is advised.
Psoriasis Area and Severity Index (PASI) score
Findings drawn, by strength
2findings · 2 compounds
- Moderate2
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
Measured, no difference found2 findings
- MelatoninMoved: no difference foundEvidence: ModeratePaper: PMID 385631312024
- Who
- adults with mild-to-moderate plaque psoriasis; melatonin cream 5% w/w vs placebo cream, applied twice daily for 8 weeks
- Dose studied
- melatonin cream 5.0% (w/w) applied twice a day
Although the PASI score in the melatonin and rosuvastatin groups compared with placebo decreased, the changes were not significant.”
Quoted verbatim from Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.RCTPermalink - fish oilMoved: no difference foundEffect, as reportedMD−0.28[−1.74 to 1.19]Evidence: ModeratePaper: PMID 318059112019
- Who
- Patients with psoriasis; three randomized trials, 337 participants, fish oil versus control
- Dose studied
- not reported
As illustrated in Fig. 3, the meta-analysis found fish oil did not produce significantly greater improvement in the PASI score than the control group (MD − 0.28; 95% confidence interval − 1.74 to 1.19).”
Quoted verbatim from Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials.meta-analysisPermalink
No row matches these filters.
How it is measured
Psoriasis Area and Severity Index (PASI), a clinician-scored composite of psoriasis extent and severity across four body regions ranging 0 to 72, reported as the change from baseline to a stated treatment endpoint. Whether the change is reported as an absolute point difference or as a percentage decrease from baseline is recorded with each finding and is not optional: the two are different reported quantities computed from the same underlying instrument.
Measured, with no finding
1 measurement
Show what was measuredHide what was measured
Psoriasis Area and Severity Index (PASI) score
decreases, PASI score reduced from mean 21.57 to 10.77 with FAE after 16 weeks, unchanged with placebo
Not recorded as a finding: this platform holds no node for the endpoint
Altmeyer et al. 16 reported a reduction of PASI score from a mean of 21·57 at baseline to 10·77 after 16 weeks of FAE treatment, whereas in the placebo group it remained the same (P < 0·001).
PMID 27087044 · one of two readings recorded this
Papers about it
As an endpoint3
Show the papersHide the papers
Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.
Skin research and technology2024PMID 38563131Via: named in the paper, as read
Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials.
BMC complementary and alternative medicine2019PMID 31805911Via: named in the paper, as read
Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments.
The British journal of dermatology2016PMID 27087044Via: named in the paper, as read
Newest
Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.
Skin research and technology2024PMID 38563131As an endpoint
Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials.
BMC complementary and alternative medicine2019PMID 31805911As an endpoint
Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments.
The British journal of dermatology2016PMID 27087044As an endpoint
Sources cited
2 papers
Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.record2024PMID 385631311 finding
Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials.record2019PMID 318059111 finding